FDA
-
-
-
-
-
-
-
Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks
-
-
-
-
-
-
-
Outlook Therapeutics resubmits drug application to FDA after September meeting
-
-
-
-
-
-
-
Outlook Therapeutics Requests Type A Meeting with FDA
-
-
-
-
-
-
-
Outlook Therapeutics (OTLK) Appoints Bob Jahr as CEO
-
-
-
-
-
-
-
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
-
-
-
-
-
-
-
Outlook Therapeutics (OTLK) Announces FDA Set August 27, 2025 as PDUFA for ONS-5010
-
-
-
-
-
-
-
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

